Hypoxia-inducible factor for the treatment of anemia in chronic kidney disease
Studies in the field of oxygen-dependent regulation of erythropoiesis provided new data on the pathogenesis of anemia associated with chronic kidney disease, which led to the development of therapeutic agents for treatment. A new class of agents for the treatment of anemia in chronic kidney disease...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Publishing House Zaslavsky
2018-10-01
|
| Series: | Počki |
| Subjects: | |
| Online Access: | http://kidneys.zaslavsky.com.ua/article/view/148522 |
| Summary: | Studies in the field of oxygen-dependent regulation of erythropoiesis provided new data on the pathogenesis of anemia associated with chronic kidney disease, which led to the development of therapeutic agents for treatment. A new class of agents for the treatment of anemia in chronic kidney disease are prolyl hydroxylase inhibitors, which stabilize hypoxia-inducible factor that is the key regulator of erythropoiesis and iron metabolism. Currently, drugs such as roxadustat (FG-4592), vadadustat (AKB-6548), daprodustat (GSK1278863) are undergoing phase III clinical trials, and molidustat (BAY 85-3934) — phase II. |
|---|---|
| ISSN: | 2307-1257 2307-1265 |